Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares China Large-Cap ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while iShares China Large-Cap ETF trades at $33.48. Which is the better fit depends on your goals.
| ALNY | FXI | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | — |
52-Week High | $491.22 | $41.75 |
52-Week Low | $278.09 | $31.59 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FXI trades at $33.48, up 0.21% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF shows mixed momentum with RSI_6 at 89.10 indicating overbought conditions. Recent news highlights China's push in AI and EVs, with a $295 billion AI infrastructure plan and a 30% NEV fleet target by 2030, potentially benefiting FXI's holdings. Support sits at $33, resistance at $34.
Outlook is cautiously optimistic due to China's tech and manufacturing rebound, though risks include U.S.-China tensions and valuation concerns. The ETF lacks current fundamental ratios, but sector growth offers upside if geopolitical and regulatory pressures ease.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
